PortalPublikationenNon-invasive fibrosis score for hepatitis delta

Non-invasive fibrosis score for hepatitis delta

Standard

Non-invasive fibrosis score for hepatitis delta. / Lutterkort, Gunnar L; Wranke, Anika; Yurdaydin, Cihan; Budde, Eva; Westphal, Max; Lichtinghagen, Ralf; Stift, Judith; Bremer, Birgit; Hardtke, Svenja; Keskin, Onur; Idilman, Ramazan; Koch, Armin; Manns, Michael P; Dienes, Hans P; Wedemeyer, Heiner; Heidrich, Benjamin.

in: LIVER INT, Jahrgang 37, Nr. 2, 02.2017, S. 196-204.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Lutterkort, GL, Wranke, A, Yurdaydin, C, Budde, E, Westphal, M, Lichtinghagen, R, Stift, J, Bremer, B, Hardtke, S, Keskin, O, Idilman, R, Koch, A, Manns, MP, Dienes, HP, Wedemeyer, H & Heidrich, B 2017, 'Non-invasive fibrosis score for hepatitis delta', LIVER INT, Jg. 37, Nr. 2, S. 196-204. https://doi.org/10.1111/liv.13205

APA

Lutterkort, G. L., Wranke, A., Yurdaydin, C., Budde, E., Westphal, M., Lichtinghagen, R., Stift, J., Bremer, B., Hardtke, S., Keskin, O., Idilman, R., Koch, A., Manns, M. P., Dienes, H. P., Wedemeyer, H., & Heidrich, B. (2017). Non-invasive fibrosis score for hepatitis delta. LIVER INT, 37(2), 196-204. https://doi.org/10.1111/liv.13205

Vancouver

Lutterkort GL, Wranke A, Yurdaydin C, Budde E, Westphal M, Lichtinghagen R et al. Non-invasive fibrosis score for hepatitis delta. LIVER INT. 2017 Feb;37(2):196-204. https://doi.org/10.1111/liv.13205

Bibtex

@article{12feb931d50546dca4f66c8c7018293f,
title = "Non-invasive fibrosis score for hepatitis delta",
abstract = "BACKGROUND & AIMS: Identifying advanced fibrosis in chronic hepatitis delta patients and thus in need of urgent treatment is crucial. To avoid liver biopsy, non-invasive fibrosis scores may be helpful but have not been evaluated for chronic hepatitis delta yet.METHODS: We evaluated eight non-invasive fibrosis scores in 100 HDV RNA-positive patients with available central histological reading. New cut-off values were calculated by using Receiver Operating Characteristics and Youden indexes. Predictors for the presence of ISHAK F3-6 were revealed by t-tests or Mann-Whitney tests.RESULTS: None of the tested scores had an area under the curve (AUROC) > 0.8 and performed according to our predefined requirements of a sensitivity of >80% and a positive predictive value (PPV) >90% - even after adaption. However, the ELF score was able to identify advanced fibrosis with a high sensitivity (93%) and PPV (81%), but relies on expensive extracellular matrix markers with bad availability in many endemic regions of HDV. Thus, we developed a novel non-invasive approach and identified low cholinesterase (P=.002), low albumin (P=.041), higher gamma glutamyl transferase, as well as older age (P<.001) as predictors of fibrosis resulting in the Delta Fibrosis Score (DFS). The DFS performed with a sensitivity of 85% and PPV of 93% with an AUROC of 0.87.CONCLUSIONS: Existing non-invasive fibrosis scores are either impracticable or do not perform well in chronic hepatitis delta patients. However, the new Delta Fibrosis Score is the first non-invasive fibrosis score specifically developed for chronic hepatitis delta and requires only standard parameters.",
keywords = "Adult, Biomarkers/blood, Biopsy, Clinical Trials, Phase II as Topic, Disease Progression, Female, Germany, Hepatitis D, Chronic/complications, Hepatitis Delta Virus, Humans, Liver/pathology, Liver Cirrhosis/diagnosis, Male, Middle Aged, Multicenter Studies as Topic, Predictive Value of Tests, ROC Curve, Randomized Controlled Trials as Topic, Severity of Illness Index, Young Adult, gamma-Glutamyltransferase/blood",
author = "Lutterkort, {Gunnar L} and Anika Wranke and Cihan Yurdaydin and Eva Budde and Max Westphal and Ralf Lichtinghagen and Judith Stift and Birgit Bremer and Svenja Hardtke and Onur Keskin and Ramazan Idilman and Armin Koch and Manns, {Michael P} and Dienes, {Hans P} and Heiner Wedemeyer and Benjamin Heidrich",
note = "{\textcopyright} 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.",
year = "2017",
month = feb,
doi = "10.1111/liv.13205",
language = "English",
volume = "37",
pages = "196--204",
journal = "LIVER INT",
issn = "1478-3223",
publisher = "Wiley-Blackwell",
number = "2",

}

RIS

TY - JOUR

T1 - Non-invasive fibrosis score for hepatitis delta

AU - Lutterkort, Gunnar L

AU - Wranke, Anika

AU - Yurdaydin, Cihan

AU - Budde, Eva

AU - Westphal, Max

AU - Lichtinghagen, Ralf

AU - Stift, Judith

AU - Bremer, Birgit

AU - Hardtke, Svenja

AU - Keskin, Onur

AU - Idilman, Ramazan

AU - Koch, Armin

AU - Manns, Michael P

AU - Dienes, Hans P

AU - Wedemeyer, Heiner

AU - Heidrich, Benjamin

N1 - © 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

PY - 2017/2

Y1 - 2017/2

N2 - BACKGROUND & AIMS: Identifying advanced fibrosis in chronic hepatitis delta patients and thus in need of urgent treatment is crucial. To avoid liver biopsy, non-invasive fibrosis scores may be helpful but have not been evaluated for chronic hepatitis delta yet.METHODS: We evaluated eight non-invasive fibrosis scores in 100 HDV RNA-positive patients with available central histological reading. New cut-off values were calculated by using Receiver Operating Characteristics and Youden indexes. Predictors for the presence of ISHAK F3-6 were revealed by t-tests or Mann-Whitney tests.RESULTS: None of the tested scores had an area under the curve (AUROC) > 0.8 and performed according to our predefined requirements of a sensitivity of >80% and a positive predictive value (PPV) >90% - even after adaption. However, the ELF score was able to identify advanced fibrosis with a high sensitivity (93%) and PPV (81%), but relies on expensive extracellular matrix markers with bad availability in many endemic regions of HDV. Thus, we developed a novel non-invasive approach and identified low cholinesterase (P=.002), low albumin (P=.041), higher gamma glutamyl transferase, as well as older age (P<.001) as predictors of fibrosis resulting in the Delta Fibrosis Score (DFS). The DFS performed with a sensitivity of 85% and PPV of 93% with an AUROC of 0.87.CONCLUSIONS: Existing non-invasive fibrosis scores are either impracticable or do not perform well in chronic hepatitis delta patients. However, the new Delta Fibrosis Score is the first non-invasive fibrosis score specifically developed for chronic hepatitis delta and requires only standard parameters.

AB - BACKGROUND & AIMS: Identifying advanced fibrosis in chronic hepatitis delta patients and thus in need of urgent treatment is crucial. To avoid liver biopsy, non-invasive fibrosis scores may be helpful but have not been evaluated for chronic hepatitis delta yet.METHODS: We evaluated eight non-invasive fibrosis scores in 100 HDV RNA-positive patients with available central histological reading. New cut-off values were calculated by using Receiver Operating Characteristics and Youden indexes. Predictors for the presence of ISHAK F3-6 were revealed by t-tests or Mann-Whitney tests.RESULTS: None of the tested scores had an area under the curve (AUROC) > 0.8 and performed according to our predefined requirements of a sensitivity of >80% and a positive predictive value (PPV) >90% - even after adaption. However, the ELF score was able to identify advanced fibrosis with a high sensitivity (93%) and PPV (81%), but relies on expensive extracellular matrix markers with bad availability in many endemic regions of HDV. Thus, we developed a novel non-invasive approach and identified low cholinesterase (P=.002), low albumin (P=.041), higher gamma glutamyl transferase, as well as older age (P<.001) as predictors of fibrosis resulting in the Delta Fibrosis Score (DFS). The DFS performed with a sensitivity of 85% and PPV of 93% with an AUROC of 0.87.CONCLUSIONS: Existing non-invasive fibrosis scores are either impracticable or do not perform well in chronic hepatitis delta patients. However, the new Delta Fibrosis Score is the first non-invasive fibrosis score specifically developed for chronic hepatitis delta and requires only standard parameters.

KW - Adult

KW - Biomarkers/blood

KW - Biopsy

KW - Clinical Trials, Phase II as Topic

KW - Disease Progression

KW - Female

KW - Germany

KW - Hepatitis D, Chronic/complications

KW - Hepatitis Delta Virus

KW - Humans

KW - Liver/pathology

KW - Liver Cirrhosis/diagnosis

KW - Male

KW - Middle Aged

KW - Multicenter Studies as Topic

KW - Predictive Value of Tests

KW - ROC Curve

KW - Randomized Controlled Trials as Topic

KW - Severity of Illness Index

KW - Young Adult

KW - gamma-Glutamyltransferase/blood

U2 - 10.1111/liv.13205

DO - 10.1111/liv.13205

M3 - SCORING: Journal article

C2 - 27428078

VL - 37

SP - 196

EP - 204

JO - LIVER INT

JF - LIVER INT

SN - 1478-3223

IS - 2

ER -